Related Experiment Video
Updated: Jan 21, 2026

Circulating MicroRNA Quantification Using DNA-binding Dye Chemistry and Droplet Digital PCR
Published on: June 26, 2016
Association between four microRNA binding site-related polymorphisms and the risk of warfarin-induced bleeding
Maryam Hosseindokht1, Mohammadali Boroumand2, Rasoul Salehi1
1Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Abstract:
Bleeding is the most serious complication of warfarin anticoagulation therapy and is known to occur even at patients with therapeutic international normalized ratio (INR) range. Recently, it has been shown that microRNAs play a significant role in pharmacogenetics by regulating genes that are critical for drug function. Interaction between microRNAs and these target genes could be affected by single-nucleotide polymorphisms (SNPs) located in microRNA-binding sites. This study focused on 3'-untranslated region (3'-UTR) SNPs of the genes involved in the warfarin action and the occurrence of bleeding complications in an Iranian population receiving warfarin. A total of 526 patients under warfarin anticoagulation therapy with responding to the therapeutic dose and maintenance of the INR in the range of 2.0-3.5 in three consecutive blood tests were included in the study. Four selected 3'-UTR SNPs (rs12458, rs7294, rs1868774 and rs34669593 located in GATA4, VKORC1, CALU and GGCX genes, respectively) with the potential to disrupt/eliminate or enhance/create microRNA-binding site were genotyped using a simple PCR-based restriction fragment length polymorphism (PCR-RFLP) method. Patients with the rs12458 AT or TT genotypes of the GATA4 gene had a lower risk of bleeding compared to patients with the AA genotype (adjusted OR: 0.478, 95% CI: 0.285-0.802, P= 0.005, OR: 0.416, 95% CI: 0.192-0.902, P= 0.026, respectively). 3'-UTR polymorphisms in other genes were not significantly associated with the risk of bleeding complications. In conclusion, the SNP rs12458A>T in the 3'UTR region of GATA4 is associated with the incidence of warfarin-related bleeding at target range of INR, likely by altering microRNA binding and warfarin metabolism. Further genetics association studies are needed to validate these findings before they can be implemented in clinical settings.
Insights
A specific gene variant (rs12458) in the GATA4 gene is linked to a reduced risk of bleeding in patients taking warfarin. This finding may impact warfarin pharmacogenetics and patient safety.
Area of Science:
- Pharmacogenetics
- Molecular Biology
- Clinical Medicine
Background:
- Warfarin anticoagulation therapy can lead to serious bleeding complications, even within the therapeutic International Normalized Ratio (INR) range.
- MicroRNAs are increasingly recognized for their role in pharmacogenetics, influencing drug metabolism by regulating target genes.
- Single-nucleotide polymorphisms (SNPs) in microRNA-binding sites can alter these interactions, potentially affecting drug response and adverse events.
Purpose of the Study:
- To investigate the association between 3'-untranslated region (3'-UTR) SNPs in warfarin-related genes and bleeding complications in an Iranian population.
- To identify specific genetic markers that may predict the risk of warfarin-induced bleeding.
Main Methods:
- Genotyping of 526 patients on warfarin therapy for four selected 3'-UTR SNPs (rs12458 in GATA4, rs7294 in VKORC1, rs1868774 in CALU, and rs34669593 in GGCX) using PCR-RFLP.
- Analysis of the association between genotypes and the incidence of bleeding complications in patients maintaining a therapeutic INR (2.0-3.5).
Main Results:
- Patients with the AT or TT genotypes of the rs12458 SNP in the GATA4 gene exhibited a significantly lower risk of bleeding compared to those with the AA genotype (adjusted ORs ranging from 0.416 to 0.478).
- No significant association was found between the other three studied SNPs (in VKORC1, CALU, and GGCX) and warfarin-related bleeding risk.
- The findings suggest that rs12458A>T polymorphism in GATA4 may influence warfarin metabolism or response, thereby affecting bleeding risk.
Conclusions:
- The SNP rs12458A>T in the 3'-UTR of the GATA4 gene is associated with a reduced incidence of warfarin-related bleeding in the studied population.
- This association is likely mediated by alterations in microRNA binding, potentially affecting warfarin metabolism.
- Further research is warranted to validate these genetic findings for potential clinical application in warfarin therapy management.
Related Concept Videos
MicroRNAs
MicroRNAs
The Equilibrium Binding Constant and Binding Strength
Ligand Binding and Linkage
Bleeding in Fresh Concrete
Bleeding can cause several issues in the concrete structure. Sometimes, the rising water gets trapped beneath large aggregate...
Hemodialysis II: Procedure and Complications

